Equity in several psychedelic drug developers rose sharply in premarket trading following Eli Lilly's announcement that it has reached a definitive agreement to acquire AtaiBeckley Inc. Market participants interpreted the deal as validation of the therapeutic approach and of the wider industry opportunity.
AtaiBeckley shares climbed 30.8% in premarket activity. Compass Pathways registered a 7.4% gain, while GH Research moved higher by 18.9%.
Under the terms disclosed, Lilly will pay $6.75 per outstanding AtaiBeckley share in cash at closing. In addition to the upfront cash payment, AtaiBeckley shareholders may receive up to $2.50 per share through a Contingent Value Right, which is tied to development and regulatory milestones for the company's lead programs, BPL-003 and VLS-01.
The upfront cash component implies an aggregate equity value for AtaiBeckley of roughly $2.8 billion, with the contingent value right representing potential incremental consideration of about $1.0 billion. The transaction is slated to close in the third quarter.
Wall-street strategists say the deal provides a direct benchmark for other companies pursuing similar therapeutic modalities. RBC Capital characterized GH Research as offering "the most direct and compelling read-through" to the acquisition, highlighting the near-identical mechanism of GH Research's lead asset, GH001, and AtaiBeckley's BPL-003. Both programs are based on 5-MeO-DMT and are targeting treatment-resistant depression.
Analyst Brian Abrahams said GH Research is positioned to begin its own registrational program later this year following feedback from the FDA.
Abrahams also noted that Lilly's willingness to pay a premium for AtaiBeckley "would set a floor for GHRS shares and also further validate the class as well as position the company as a compelling opportunity for other strategics."
RBC Capital maintained an Outperform rating on GH Research and left a $40 price target in place. The firm cited the scalability of psychedelic-based treatments, apparent regulatory amenability, and what it described as reduced concerns about intellectual property vulnerability in the wake of Lilly's acquisition.
The market reaction to the transaction underscores investor interest in companies developing novel psychiatric therapeutics and highlights how a strategic acquisition can alter perceptions of risk and value across a specialized subsector of biopharma.
Note: This article reports price moves, deal terms, analyst commentary, and expected timing as disclosed in the announcement and subsequent analyst notes.